التفاصيل البيبلوغرافية
| العنوان: |
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). |
| المؤلفون: |
Lenders, Malte, Nordbeck, Peter, Kurschat, Christine, Karabul, Nesrin, Kaufeld, Jessica, Hennermann, Julia B., Patten, Monica, Cybulla, Markus, Müntze, Jonas, Üçeyler, Nurcan, Liu, Dan, Das, Anibh M., Sommer, Claudia, Pogoda, Christian, Reiermann, Stefanie, Duning, Thomas, Gaedeke, Jens, Stumpfe, Katharina, Blaschke, Daniela, Brand, Stefan‐Martin |
| المصدر: |
Clinical Pharmacology & Therapeutics; Aug2020, Vol. 108 Issue 2, p326-337, 12p |
| مصطلحات موضوعية: |
ANGIOKERATOMA corporis diffusum, LYSOSOMES, HYPOTENSION, GLOMERULAR filtration rate, GALACTOSIDASES, LYSOSOMAL storage diseases, SCIENTIFIC observation |
| مستخلص: |
Fabry's disease (FD) is an X‐linked lysosomal storage disorder caused by the deficient activity of the lysosomal enzyme α‐galactosidase A (α‐Gal A) leading to intracellular accumulation of globotriaosylceramide (Gb3). Patients with amenable mutations can be treated with migalastat, a recently approved oral pharmacologic chaperone to increase endogenous α‐Gal A activity. We assessed safety along with cardiovascular, renal, and patient‐reported outcomes and disease biomarkers in a prospective observational multicenter study after 12 months of migalastat treatment under "real‐world" conditions. Fifty‐nine (28 females) patients (34 (57.6%) pretreated with enzyme replacement therapy) with amenable mutations were recruited. Migalastat was generally safe and well tolerated. Females and males presented with a reduction of left ventricular mass index (primary end point) (−7.2 and −13.7 g/m2, P = 0.0050 and P = 0.0061). FD‐specific manifestations and symptoms remained stable (all P > 0.05). Both sexes presented with a reduction of estimated glomerular filtration rate (secondary end point) (−6.9 and −5.0 mL/minute/1.73 m2; P = 0.0020 and P = 0.0004, respectively), which was most prominent in patients with low blood pressure (P = 0.0271). α‐Gal A activity increased in male patients by 15% from 29% to 44% of the normal wild‐type activity (P = 0.0106) and plasma lyso‐Gb3 levels were stable in females and males (P = 0.3490 and P = 0.2009). Reevaluation of mutations with poor biochemical response revealed no marked activity increase in a zero activity background. We conclude that therapy with migalastat was generally safe and resulted in an amelioration of left ventricular mass. In terms of impaired renal function, blood pressure control seems to be an unattended important goal. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
